Importance of Bleeding Disorder in the Management of Dental Patients
Mohammad Ali1, M Selimuzzaman2, Sumaya Marzan3

Abstract
Dental practitioners must be aware of the importance of bleeding disorders in the management of dental patients. Initial recognition of such bleeding disorders, knowledge of their possible systemic causes and clear idea in the management of the cases for dental treatment or when to refer those cases to secondary care, plays a crucial and important role in reducing potential complications and negative side effects. The purpose of this article is to review common bleeding disorders, complications and their management that dentists might find in their daily dental practice.

Key Words: Bleeding disorders, complications, dental health care.

Introduction
Dental practitioners must be aware of the impact of bleeding disorders on the management of their patients. Proper dental and medical evaluation of patients is therefore necessary before treatment, especially if an invasive dental procedure is planned. Patient evaluation and history should begin with standard medical questionnaires. Patients should be queried about any previous unusual bleeding episode after surgery or injury.

The patient should be asked for any history of significant and prolonged bleeding after dental extraction or bleeding from gingivae. A history of nasal or oral bleeding should be noted. Many bleeding disorders, such as hemophilia and von Willebrand disease, run in families; therefore, a family history of bleeding disorders should be carefully elicited.

A complete drug history is important. If a patient is taking anticoagulant drugs, it will be important to consult his or her physician before any major surgical procedure. In addition, a number of medications may interfere with hemostasis and prolonged bleeding. Drugs of abuse, such as alcohol or heroin, may also cause excess bleeding by causing liver damage resulting in altered production of coagulation factors. Patients with liver disease may have jaundice, spider nevi, ascites and other signs of impaired hepatic function. A cardiac patient can show tachycardia or hypertension, which may make hemostasis more difficult to achieve. When a bleeding disorder is suspected, laboratory investigations, including blood counts and clotting studies, should be carried out.

Preoperative laboratory test
Preoperative laboratory tests of the hemostatic system are:

• bleeding time to determine platelet function (normal range: 2-7 minutes)
• activated partial thromboplastin time to evaluate the intrinsic coagulation pathway (normal range: 25 ± 10 seconds)
• Prothrombin time (normal range 12-15 seconds) with international normalized ratio (normal range: 1.0) to measure the function of extrinsic coagulation pathway.
• platelet count to quantify platelet function (normal range: 150,000–450,000/¼L).

1. Assistant Professor, Department of Pediatric Dentistry, Bangladesh Institute of Child Health (BICH), Dahaka Shishu (Children) Hospital, Dhaka.
2. Professor & Head, Department of Pediatric Haematology and Oncology, Bangladesh Institute of Child Health (BICH), Dahaka Shishu (Children) Hospital
3. Dental Surgeon, Shahali Dental Clinic.
Correspondence to: Dr. Mohammad Ali, Assistant Professor, Department of Paediatric Dentistry, Bangladesh Institute of Child Health (BICH), Dahaka Shishu (Children) Hospital, Sher-e-Bangla Nagar, Dhaka-1207. Cell: 01819271054, E-mail: ali.mohammad3500@gmail.com
Received: 11 June 2018; Accepted: 12 July 2018
Types of Bleeding Disorders

Bleeding disorders can be classified as coagulation factor deficiencies, platelet disorders, vascular disorders, or fibrinolytic defects (Table I).³,⁴

Among the congenital coagulation defects, hemophilia A, hemophilia B (Christmas disease) and von Willebrand’s disease are the most common. Hemophilia A is due to a deficiency of clotting factor VIII or antihemophilic factor. It is an inherited X-linked recessive trait found in males. Symptoms may include delayed bleeding, ecchymosis, deep hematomas, epistaxis, spontaneous gingival bleeding and hemarthrosis. A factor VIII level of 6% to 30% of normal factor activity (mild hemophilia) is associated with bleeding during surgery or trauma; 1% to 5% with bleeding after mild injury; and <1% (severe hemophilia) with spontaneous bleeding ³.

Management

Management of hemophilia A among patients undergoing dental surgery consists of increasing factor VIII levels, replacing factor VIII and inhibiting fibrinolysis (Table II).

Options for factor VIII replacement are factor VIII concentrates, fresh frozen plasma and cryoprecipitate.

Antifibrinolytic therapy can be used postoperatively to protect the formed blood clot. Epsilon-aminocaproic acid and tranexamic acid are the common agents used. Tranexamic acid in an oral rinse helps prevent postoperative bleeding from surgical wounds.

| Name of test                      | Evaluate                              | Normal values                  | Prolonged in                                                                 |
|----------------------------------|---------------------------------------|--------------------------------|----------------------------------------------------------------------------|
| Bleeding time                    | To assess the platelet and normal blood vessel functions | 2.9 minutes, Depend on the Method used | Platelet disorders, vessel-wall disorders, fibrinogen disorders and Von Willebrand’s disease |
| Activated partial thromboplastin time (APTT) | The intrinsic pathway of blood coagulation (which includes Factor II, V, X) | 25± 10 second | Heparin treatment, liver diseases, hemophilia, DIC, massive transfusion and in some auto-imune treatments, such as in lupus anticoagulant |
| Prothrombin time (PT)            | The extrinsic pathway (Factors II, V, VII, X and fibrinogen) | 12-15 seconds | Warfarin treatment, liver disease, vitamin K deficiency, DIC |

### Table I

*Laboratory-based investigations*

| Name of test | Evaluate | Normal values | Prolonged in |
|--------------|----------|---------------|--------------|
| Bleeding time | To assess the platelet and normal blood vessel functions | 2.9 minutes, Depend on the Method used | Platelet disorders, vessel-wall disorders, fibrinogen disorders and Von Willebrand’s disease |
| Activated partial thromboplastin time (APTT) | The intrinsic pathway of blood coagulation (which includes Factor II, V, X) | 25± 10 second | Heparin treatment, liver diseases, hemophilia, DIC, massive transfusion and in some auto-imune treatments, such as in lupus anticoagulant |
| Prothrombin time (PT) | The extrinsic pathway (Factors II, V, VII, X and fibrinogen) | 12-15 seconds | Warfarin treatment, liver disease, vitamin K deficiency, DIC |

### Table II

*Common bleeding disorders*

| Coagulation factor deficiencies | Congenital  |
|---------------------------------|-------------|
|                                 | Hemophilia A and B |
|                                 | von Willebrand's disease |
| Acquired                        | Liver disease |
|                                 | Vitamin K deficiency, warfarin use |
|                                 | Disseminated intravascular coagulation |

| Platelet disorders | Quantitative disorder (thrombocytopenia) |
|--------------------|------------------------------------------|
|                    | Immune-mediated                          |
|                    | Idiopathic                               |
|                    | Drug-induced                             |
|                    | Collagen vascular disease                |
|                    | Non-immune-mediated                     |
|                    | Disseminated intravascular coagulation   |
|                    | Leukemia                                 |

| Qualitative disorder | Congenital  |
|----------------------|-------------|
|                      | von Willebrand disease |
|                      | Acquired     |
|                      | Drug-induced  |
|                      | Liver disease |
|                      | Alcoholism   |

| Vascular disorders  | Scurvy |
|---------------------|-------|
|                     | Purpura |

| Fibrinolytic defects | Streptokinase therapy |
|----------------------|-----------------------|
Postoperative use of epsilon aminocaproic acid can considerably reduce the level of factor required to control bleeding when used in conjunction with presurgical infusion of factor required to control bleeding when used in conjunction with presurgical infusion of factor VIII concentrate.\textsuperscript{5}

Hemophilia B is the result of factor IX deficiency. It is managed by replacement therapy with highly purified, virally inactivated factor IX concentrates. Prothrombin complex concentrates can also be used for factor IX replacement. von Willebrand disease is the most common hereditary coagulation disorder with an incidence of 1 in 10,000. It is not sex linked. It is classified as Type I to Type III and may vary in severity. For mild conditions, use of DDAVP may be sufficient, but severe disease warrants factor VIII replacement.

Other than congenital diseases, coagulation defects may be acquired and from a variety of sources (Table IV). In liver diseases, the synthesis of clotting factors may be reduced due to parenchymal damage or obstruction.\textsuperscript{6} These patients may have a variety of bleeding disorders depending on the extent of their liver disease. Management options for hemostatic defects in liver disease\textsuperscript{5} include vitamin K and fresh frozen plasma infusion (immediate but temporary effect) for prolonged prothrombin time and partial thromboplastin time; cryoprecipitate for replacement of factor VIII deficiency; and replacement therapy for disseminated intravascular coagulation. Patients suffering from viral hepatitis are a potential source of cross infection, and necessary precautions should be taken during procedures. Drug doses frequently need to be modified in these patients due to impaired liver function. The patient’s physician should be consulted before making any changes in the drug regimen.

| Table III | Presurgery treatment for Hemophilia A\textsuperscript{4} |
| Condition | Treatment and dose | Potential complication |
|------------|-------------------|------------------------|
| Mild bleeding | Dose: 15 U/kg factor VIII every 8-12 hours for 1-2 days Target: 30% of normal level | Hemarthrosis, oropharyngeal or dental bleeding, epistaxis, hematuria |
| Major bleeding | Dose: 50 U/kg factor VIII every 8-12 hours for 7-14 days Target: 80-100% of normal level | Same potential complications as for mild bleeding, as well as central nervous system hemorrhage, gastrointestinal bleeding |

| Table IV | Systemic diseases causing coagulopathies\textsuperscript{1} |
| Disease | Common causes | Resulting coagulation defect |
|----------|----------------|-----------------------------|
| Renal failure and uremia | Diabetes mellitus | Inhibition of adhesion and primary aggregation of platelets from glycoprotein IIb-IIIa deficit |
| Hepatic failure | Alcohol abuse, Hepatitis B and C, Cancer(e.g.), Hepatocellular carcinoma | Obstructive jaundice: deficiency of vitamin K-dependent factors II, VII, IX and X Loss of liver tissue and all clotting factors except VIII and von Willebrand factor |
| Bone marrow failure | Renal failure and uremia | Reduced number of functioning platelets Anemia from bone marrow suppression |
Coagulopathies can be drug induced. Warfarin, low-molecular-weight heparin and dicumarol (coumadin) are the most commonly used anticoagulant drugs. Treatment must be modified in accordance with the medications that the patient is taking and their impact on coagulation. Platelet disorders can be hereditary or acquired and may be due to decreased platelet production, excess consumption or altered function. The most common clinical features are bleeding from superficial lesions and cuts, spontaneous gingival bleeding, petechiae, ecchymosis and epistaxis. The minimum blood platelet level before dental surgical procedures is approximately 50,000/μL; extensive surgery may require > 100,000/μL. Replacement therapy may be required if the count is below this level. Usually, platelet transfusion is carried out 30 minutes before surgery. In patients with platelet levels below 100,000/μL, prolonged oozing may occur, but local measures are usually sufficient to control the bleeding. In cases of idiopathic thrombocytopenic purpura, an acquired platelet disorder, oral systemic steroids may be prescribed 7-10 days before surgery to increase the platelet count to safe levels.9 Vascular defects are rare and usually associated with mild bleeding confined to skin or mucosa.10 Scurvy, hereditary hemorrhagic telangiectasia and other vascular defects are usually treated with laser ablation, embolization or coagulation. Recognizing vascular lesions during examination, aspiration or advanced imaging may lead to modification of treatment planning.

### Table V

*Principal agents for systemic management of patients with bleeding disorders*

| Agent                | Description                                      | Common indications                                                                 |
|----------------------|--------------------------------------------------|------------------------------------------------------------------------------------|
| Platelets            | 1 unit=50mL; may raise count by 6,000             | Platelet count                                                                    |
|                      |                                                  | <10,000 in nonbleeding individuals                                                  |
|                      |                                                  | <50,000 in presurgical level                                                       |
|                      |                                                  | >50,000 in actively bleeding individuals                                            |
| Fresh frozen plasma  | 1 unit = 150-250 mL                               | Undiagnosed bleeding disorder                                                     |
|                      | 1 hour to thaw                                    | with active bleeding                                                               |
|                      | Contains factors II, VII, IX, XI, XII, XIII, and  | Severe liver disease                                                              |
|                      | heat-labile V and VII                             | When transfusing >10 units of blood                                                |
| Cryoprecipitate      | 1 unit = 10-15 mL                                 | Hemophilia A, von Willebrand's disease, Fibrinogen deficiency                       |
| Factor VIII concentrate | 1 unit raise factor VIII level 2%             | Hemophilia A, with active bleeding or presurgery; some case of von Willebrand's disease |
|                      | Heat-treated contains von Willebrand's factor    |                                                                                   |
| Factor IX concentrate | 1 unit raises factor IX level 1-1.5%             | Hemophilia B, with bleeding or presurgery                                           |
|                      | Contains factors II, VII, IX, and X              |                                                                                   |
| Tranexamic acid      | Antifibrinolytic: 4.8% mouth rinse Systemic:       | Adjunct to support clot formation for any bleeding disorder                        |
|                      | 25 mg/kg every 8 hours                            |                                                                                   |

### Table VI

*Local hemostatic agents*

| Brand name            | Generic name or description                      |
|-----------------------|--------------------------------------------------|
| Gelfoam (Pfizer, Markham) | Absorbant gelatin sponge material               |
| Surgicel (Ethicon, Markham) | Oxidized cellulose                               |
| Tissel (Baxter, Mississauga) | Fibrin sealant                                  |
| Thrombostat (Pfizer)    | Topical thrombin                                 |
| Cyklokapron (Pfizer)    | Tranexamic acid                                  |
| Amicar (with, Markham)  | Epsilone-aminocaproic acid                       |
Oral Findings
Platelet deficiencies can cause ecchymosis in oral mucosa and promote spontaneous gingival bleeding. These disorders may be present alone or in conjunction with gingival hyperplasia in cases of leukemia. Hemosiderin and other blood degradation products can cause brown deposits on the surface of teeth due to chronic bleeding.

People with Hemophilia may have multiple bleeding events over their lifetime. The frequency of bleeding depends on the severity of hemophilia. Hemarthrosis of the temporomandibular joint is uncommon. The incidence of dental caries and periodontal diseases is higher in patients with bleeding disorders, which may be because of lack of effective oral hygiene and professional dental care due to fear of oral bleeding.

Dental Management
The management of patients with bleeding disorders depends on the severity of the condition and the invasiveness of the planned dental procedure. If the procedure has limited invasiveness and the patient has a mild bleeding disorder, only slight or no modification will be required. In patients with severe bleeding disorders, the goal is to minimize the challenge to the patient by restoring the hemostatic system to acceptable levels and maintaining hemostasis by local and adjunctive methods. The patient’s physician should be consulted before invasive treatment is undertaken. In patients with drug-induced coagulopathies, drugs may be stopped or the doses modified. For irreversible coagulopathies, replacement of missing factors may be necessary (Table IV).

Pain Control
In patients with coagulopathies, nerve-block anesthetic injections are contraindicated unless there is no better alternative and prophylaxis is provided, as the anesthetic solution is deposited in a highly vascularized area, which carries a risk of hematoma formation. The commonly used blocks require minimum clotting factor levels of 20% to 30%. Extravasation of blood in the oropharyngeal area by an inferior alveolar block or in the pterygoid plexus can produce gross swelling, pain, dysphasia, respiratory obstruction and risk of death from asphyxia. Anesthetic infiltration and intraligamentary anesthesia are potential alternatives to nerve block in many cases. An anesthetic with a vasoconstrictor should be used when possible. Alternative techniques, including sedation with diazepam or nitrous oxide—oxygen analgesia, can be employed to reduce or eliminate the need for anesthesia. Patients undergoing extensive treatment requiring factor replacement may be treated under general anesthesia in a hospital operating room.

Oral Surgery
Surgical procedures carry the highest risk of bleeding, and safety precautions are needed. For coagulopathies, transfusion of appropriate factors to 50% to 100% of normal levels is recommended when a single bolus infusion is used in an outpatient setting. In patients with hemophilia, additional postoperative factor maintenance may be required after extensive surgeries. This can be done with factor infusion, cryoprecipitate or fresh frozen plasma depending on the patient’s condition. The patient’s hematologist should be consulted before planning, and patients with severe disease should be treated in specialty centres.

Local hemostatic agents (Table V) and techniques such as pressure, surgical packs, sutures and surgical stents may be used individually or in combination and may assist in the local delivery of hemostatic agents, such as topical thrombin and vasoconstrictors. However, caution is needed with the use of vasoconstrictors because of the risk of rebound vasodilatation, which may increase late bleeding risk. The use of absorbable hemostatic materials may favour clot formation and stability. However, these materials also carry a risk of infection and may delay healing; they should therefore be avoided in immunosuppressed patients. Topical thrombin is an effective agent when applied directly on bleeding wound as it converts fibrinogen to fibrin and allows rapid hemostasis in a wound. Topical fibrin glue can reduce the amount of factor replacement needed when used alonged with antifibrinolytic agents.

The patient’s physician should be consulted before any decision is made to modify the patient’s drug regimen, and the potential risk-benefit ratio should be determined. For patients taking warfarin, their international normalized ratio (INR) should be measured before a surgical procedure. The normal therapeutic range is 2.0-3.0. According to current recommendations, most oral surgical procedures can
be performed without altering the warfarin dose if the INR is less than 3.0.\textsuperscript{19} If INR values are greater than 3.0, physician referral is suggested. It is important to consider the risk of reducing the level of anticoagulation in patients on warfarin due to the risk of a thromboembolic event.\textsuperscript{20} Patients taking heparin are often those who are on hemodialysis due to end-stage renal disease. Heparin has a short half-life (about 5 hours) and patients can often be treated safely on the days between dialysis.

**Periodontal Procedures**

Periodontal health is of critical importance in patients with bleeding disorders\textsuperscript{3} as inflamed and hyperemic gingival tissues are at increased risk of bleeding. Periodontitis may cause tooth mobility and warrant extraction, which may be a complicated procedure in these patients. Patients with coagulopathies may neglect their oral health due to fear of bleeding during tooth brushing and flossing, which leads to increased gingivitis, periodontitis and caries.

Periodontal probing, subgingival scaling and polishing can be done normally without the risk of significant bleeding. Factor replacement is seldom needed for subgingival scaling and root planing if these procedures are done carefully. Ultrasonic instrumentation may result in less tissue trauma. For severely inflamed tissues, initial treatment with chlorhexidine mouth washes and gross debridement are recommended to reduce tissue inflammation before deep scaling.\textsuperscript{21} Factor replacement may be required before extensive periodontal surgery and use of nerve blocks.

**Restorative and Endodontic Procedures**

General restorative procedures do not pose a significant risk of bleeding. Care should be taken to avoid injuring the gingiva while placing rubber dam clamps, matrices and wedges.

Endodontic therapy is preferred over extraction whenever possible in these patients. Endodontic therapy does not usually pose any significant risk of bleeding and can be performed routinely. Endodontic surgical procedures may require factor replacement therapy.

**Prosthodontic and orthodontic Procedures**

These procedures do not usually involve risk of bleeding. Trauma should be minimized by careful post-insertion adjustments. Oral tissue should be handled carefully during the various clinical stages prosthesis and orthodontic therapy.

**Choice of Medications**

Many medications prescribed in dental practice, especially ASA, may interfere with hemostasis. In addition, many drugs interact with anticoagulants, increasing their potency and the risk of bleeding. When used for prolonged periods, ASA and nonsteroidal anti-inflammatory drugs (NSAIDS) can increase the effect of warfarin. Penicillins, erythromycin, metronidazole, tetracyclines and miconazole also have potentiating effects on warfarin. Care should be taken when prescribing these drugs to patients with bleeding tendencies or those receiving anticoagulant therapy, and it may be desirable to consult the patient’s physician before planning the dose regimen.

**Conclusion**

For proper dental treatment specially when an invasive surgical procedure to be planned in bleeding disorder patients adequate knowledge for management the patients is very important. Knowledge about causes of bleeding disorder, management procedure, when and where to refer the cases for secondary care plays an important role in reducing potential complications and negative side effects.

**References**

1. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 1: Coagulopathies from systemic disease. Br Dent J 2003; 195(8): 439-45.

2. Meechan JG, Greenwood M. General medicine and surgery for dental practitioners Part 9: haematology and patients with bleeding problems. Br Dent J 2003; 195(6): 305-10.

3. Patton LL. Bleeding and clotting disorders. In: Burket’s oral medicine: diagnosis and treatment. 10th ed. Hamilton (ON): BC Decker; 2003. p. 454-77.

4. Blinder MA. Bleeding disorders. [Web site of the Washington University School of Medicine]. Available from URL: http://hematology.im.wustl.edu/conferences/presentations/blinder080604.ppt.

5. Webster WP, McMillan CW, Lucas ON, and others. Dental management of the bleeder patient. A comparative review of replacement therapy. In: Ala F, Denson LW, editors. Hemophilia. Amsterdam: Excerpta Medica; 1973. p. 33-7.
6. Walsh PN, Rizza CR, Matthews JM, Eipe J, Kernoff PB, Coles MD, and others. Epsilon-aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol 1971; 20(5): 463-75.

7. Walsh PN, Rizza CR, Evans BE, Aledort LM. The therapeutic role of epsilon Aminocaproic acid (EACA) for dental extractions in hemophiliacs. Ann N Y Acad Sci 1975; 240: 267-76.

8. Golla K, Epstein JB, Cabay RJ. Liver disease: current perspectives on medical and dental management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98(5): 516-21.

9. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 2: Coagulopathies from drugs. Br Dent J 2003; 195(9): 495-501.

10. Flint SR, Keith O, Scully C. Hereditary hemorrhagic telangiectasia: family study and review. Oral Surgery Oral Med Oral Pathol 1988; 66: 440-44.

11. Nazif M. Local anesthesia for patients with hemophilia. ASDC J Dent Child 1970; 37(1): 79-84.

12. Webster WP, Roberts HR, Penick GD. Dental care of patients with hereditary disorders of blood coagulation. In: Rantoff OD, editor. Treatment of hemorrhagic disorders. New York: Harper & Row; 1968. p.93-110.

13. Archer WH, Zubrow HJ. Fatal hemorrhage following regional anesthesia for operative dentistry in a hemophiliac. Oral Surg Oral Med Oral Pathol 1954; 7(5): 464-70.

14. Leatherdale RA. Respiratory obstruction in haemophilic patients. Br Med J 1960; 30(5182): 1316-20.

15. Bogdan CJ, Strauss M, Ratnoff OD. Airway obstruction in hemophilia (factor VIII deficiency): a 28-year institutional review. Laryngoscope 1994; 104(7): 789-94.

16. Rackoz M, Mazar A, Varon D, Spierer S, Blinder D, Martinowitz U. Dental extractions in patients with bleeding disorders. The use of fibrin glue. Oral Surg Oral Med Oral Pathol 1993; 75(3): 280-82.

17. Martinowitz U, Schulman S. Fibrin sealant in surgery of patients with hemorrhagic diathesis. Thromb Haemost 1995; 74(1): 486-92.

18. Martinowitz U, Schulman S, Horoszowski H, Heim M. Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. Clin Orthop Relat Res 1996; (328): 65-75.

19. Davis BR, Sandor GK. Use of fibrin glue in maxillofacial surgery. J Otolaryngol 1998; 27(2): 107-12.

20. Dental practitioners’ formulary 2002–2004. London: British Dental Association, British Medical Association, Royal Pharmaceutical Society of Great Britain. p.D8,117-9.

21. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc 2000; 131(1): 77-81.

22. Webster WP, Courtney RM. Diagnosis and treatment of periodontal disease in the hemophiliac. In: Proceedings, Dental Hemophilia Institute. New York: National Hemophilia Foundation; January 1968.